Perspective Therapeutics
CATX
45 hedge funds and large institutions have $6.78M invested in Perspective Therapeutics in 2021 Q4 according to their latest regulatory filings, with 10 funds opening new positions, 6 increasing their positions, 9 reducing their positions, and 6 closing their positions.
311% more capital inflows, than outflows
Capital inflows: $1.16M | Capital outflows: $282K
67% more first-time investments, than exits
New positions opened: 10 | Existing positions closed: 6
5% more funds holding
Funds holding: 43 → 45 (+2)
1.17% more ownership
Funds ownership: 11.16% → 12.33% (+1.2%)
33% less repeat investments, than reductions
Existing positions increased: 6 | Existing positions reduced: 9
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Perkins Capital Management
Wayzata,
Minnesota
|
+$666K |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$88.1K |
| 3 |
Highland Private Wealth Management
Bellevue,
Washington
|
+$66.7K |
| 4 |
UBS Group
Zurich,
Switzerland
|
+$42.4K |
| 5 |
Bard Associates
Chicago,
Illinois
|
+$37.9K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
-$113K |
| 2 |
Bridgeway Capital Management
Houston,
Texas
|
-$48K |
| 3 |
Marshall Wace
London,
United Kingdom
|
-$31K |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
-$29K |
| 5 |
Chicago Partners Investment Group
Chicago,
Illinois
|
-$20K |
CATX Hedge Fund Activity: Q4 2021 in Review
45 of the 6,522 institutional investors tracked by Wall St. Rank reported a position in Perspective Therapeutics (CATX) for Q4 2021, worth a combined $6.78M — down 32% from $10M a quarter earlier.
Buyers outnumbered sellers: 10 funds opened new CATX positions and 6 closed out — a net gain of 4 holders — while 6 added to existing stakes and 9 trimmed.
The largest buyer was Perkins Capital Management, adding an estimated $666K. The largest seller was Renaissance Technologies, cutting an estimated $113K.
- 45 institutional investors held Perspective Therapeutics (CATX) as of Q4 2021, up from 43 in Q3 2021.
- Funds reported $6.78M of Perspective Therapeutics stock for Q4 2021, down 32% quarter-over-quarter.
- 10 funds opened new Perspective Therapeutics positions in Q4 2021 and 6 closed out, a net change of +4 holders.
- The largest Perspective Therapeutics buyer in Q4 2021 was Perkins Capital Management, an estimated $666K added.
- The largest Perspective Therapeutics seller in Q4 2021 was Renaissance Technologies, an estimated $113K sold.
Based on aggregated 13F filings for Q4 2021.